167 related articles for article (PubMed ID: 27718067)
1. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.
Tischer B; Huber R; Kraemer M; Lacouture ME
Support Care Cancer; 2017 Feb; 25(2):651-660. PubMed ID: 27718067
[TBL] [Abstract][Full Text] [Related]
2. Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials: A Systematic Review.
Shaigany S; Mastacouris N; Tannenbaum R; Strunk A; Luan C; Burshtein J; Burshtein A; Carvajal R; Garg A; Alloo A
JAMA Dermatol; 2024 Jun; 160(6):651-657. PubMed ID: 38506826
[TBL] [Abstract][Full Text] [Related]
3. PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients.
Gu S; Menzer C; Hay JL; Pena C; Dusza S; Lacouture ME; Markova A
Support Care Cancer; 2023 May; 31(6):337. PubMed ID: 37183206
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature.
Belzer A; Pach JJ; Valido K; Leventhal JS
Am J Clin Dermatol; 2024 May; 25(3):435-445. PubMed ID: 38366030
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
6. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.
Barton-Burke M; Ciccolini K; Mekas M; Burke S
Nurs Clin North Am; 2017 Mar; 52(1):83-113. PubMed ID: 28189168
[TBL] [Abstract][Full Text] [Related]
7. Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights.
Fabbrocini G; Panariello L; Caro G; Cacciapuoti S
Skin Appendage Disord; 2015 Mar; 1(1):31-7. PubMed ID: 27171241
[TBL] [Abstract][Full Text] [Related]
8. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy.
Seervai RNH; Cho WC; Chu EY; Marques-Piubelli ML; Ledesma DA; Richards K; Heberton MM; Nelson KC; Nagarajan P; Torres-Cabala CA; Prieto VG; Curry JL
J Cutan Pathol; 2022 Jan; 49(1):61-81. PubMed ID: 34622477
[TBL] [Abstract][Full Text] [Related]
9. Patient-Reported Dental Safety Events: A South African Perspective.
Obadan-Udoh E; Van der Berg-Cloete S; Ramoni R; Kalenderian E; White JG
J Patient Saf; 2021 Dec; 17(8):e866-e873. PubMed ID: 29369072
[TBL] [Abstract][Full Text] [Related]
10. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
[TBL] [Abstract][Full Text] [Related]
12. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.
Tischer B; Bilang M; Kraemer M; Ronga P; Lacouture ME
Support Care Cancer; 2018 Apr; 26(4):1169-1179. PubMed ID: 29116406
[TBL] [Abstract][Full Text] [Related]
13. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
14. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.
Peng Y; Li Q; Zhang J; Shen W; Zhang X; Sun C; Cui H
Biosci Trends; 2019 Jan; 12(6):537-552. PubMed ID: 30555112
[TBL] [Abstract][Full Text] [Related]
15. The state of the art in secondary pharmacology and its impact on the safety of new medicines.
Brennan RJ; Jenkinson S; Brown A; Delaunois A; Dumotier B; Pannirselvam M; Rao M; Ribeiro LR; Schmidt F; Sibony A; Timsit Y; Sales VT; Armstrong D; Lagrutta A; Mittlestadt SW; Naven R; Peri R; Roberts S; Vergis JM; Valentin JP
Nat Rev Drug Discov; 2024 May; ():. PubMed ID: 38773351
[TBL] [Abstract][Full Text] [Related]
16. Patient symptoms, self-management, and unscheduled healthcare use during the first 6 months of targeted oral anticancer agent therapy: protocol for a mixed-methods US study.
Rizvi-Toner A; Coe AB; Friese CR; Manojlovich M; Wallner L; Farris KB
BMJ Open; 2024 Feb; 14(2):e081375. PubMed ID: 38355181
[TBL] [Abstract][Full Text] [Related]
17. Home-based multidisciplinary interventions on skin adverse reactions in EGFR-TKI-treated patients with lung cancer: a protocol for a randomised controlled trial.
Du R; Yang H; Zhou H; Ma L; Getu MA; Chen C; Wang T
BMJ Open; 2022 Nov; 12(11):e063921. PubMed ID: 36442902
[TBL] [Abstract][Full Text] [Related]
18. Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Hsu HT; Yu CC; Lee YH; Chan JC; Chu CY
Support Care Cancer; 2022 Nov; 30(11):9211-9219. PubMed ID: 36056941
[TBL] [Abstract][Full Text] [Related]
19. The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.
Du R; Yang H; Zhou H; Ma L; Getu MA; Chen C; Wang T
BMC Cancer; 2022 May; 22(1):491. PubMed ID: 35505288
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
